



Press release Feb. 14, 2011

Genovis year-end report delayed

The Board of Directors of Genovis has decided to delay publication of the year-end report for 2010. The previously announced reporting date for the year-end report was February 15, but the Board of Directors has decided that the company will publish the year-end report on February 23 instead.

For more information, contact:
Sarah Fredriksson, CEO, Genovis AB
+46-46-10 12 30
sarah.fredriksson@genovis.com

Genovis is a biotech company on the leading edge of nanotechnology and nanoparticles. The company's patented nano-induced magnetic transfer (NIMT®) technology was developed to facilitate effective preclinical research for the life science industry. Genovis shares are listed on the First North OMX Nordic Exchange. Mangold Fondkommission is our certified advisor and liquidity guarantor.